Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Evkeeza - opinion on variation to marketing authorisation

Evkeeza - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

evinacumab
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Evkeeza
  • More information on Evkeeza

Opinion

On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Evkeeza. The marketing authorisation holder for this medicinal product is Ultragenyx Germany GmbH.

The CHMP adopted an extension to the existing indication to include treatment of patients aged 5 years and older with homozygous familial hypercholesterolaemia (HoFH). For information, the full indications for Evkeeza will be as follows:1

Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescentpaediatric patients aged 512 years and older with homozygous familial hypercholesterolaemia (HoFH).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1New text in bold, removed text as strikethrough

CHMP post-authorisation summary of positive opinion for Evkeeza (II-11)

AdoptedReference Number: EMA/CHMP/489254/2023

English (EN) (93.66 KB - PDF)

First published: 10/11/2023
View

Key facts

Name of medicine
Evkeeza
EMA product number
EMEA/H/C/005449
Active substance
Evinacumab
International non-proprietary name (INN) or common name
evinacumab
Therapeutic area (MeSH)
Hypercholesterolemia
Anatomical therapeutical chemical (ATC) code
C10AX

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.

Marketing authorisation holder
Ultragenyx Germany GmbH
Date of opinion
09/11/2023
Status
Positive

News on Evkeeza

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
15/11/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023
10/11/2023

More information on Evkeeza

  • Evkeeza
This page was last updated on 10/11/2023

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union